Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 19, 2007

Genelabs Technologies Regains Rights to Prestara in Japan

  • Genelabs Technologies regained full development and licensing rights in Japan for its investigational lupus drug Prestara™ (GL701), under the terms of a termination agreement between the company and Mitsubishi Tanabe Pharma. In October, Mitsubishi Tanabe Pharma was formed by the merger of Tanabe Seiyaku and Mitsubishi Pharma. 

    Genelabs and Tanabe Seiyaku signed a collaboration and license agreement in January 2004. The agreement provided that Tanabe was responsible for conducting all development work and obtaining regulatory approval for Prestara in Japan.

    Under the terms of the agreement, Genelabs received an initial $2 million nonrefundable license fee. No milestone payments were ever made. Mitsubishi Tanabe Pharma continues to own common stock in Genelabs, which were purchased for $2.6 million in connection with the collaboration and license agreement.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »